Scholarlink

Background <p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to branched-chain amino acid (BCAA) dysmetabolism and ferroptosis, and exercise is considered protective, yet the underlying mechanisms remain unclear.</p> Methods <p>Integrated bioinformatic analyses of public datasets were performed to identify key regulators of MASLD. Hepatic inositol hexakisphosphate kinase 3 (IP6K3) expression was examined in liver samples from patients with MASLD as well as mice. The functional role of IP6K3 was assessed by either hepatocyte-specific <i>Ip6k3</i> deletion or exercise intervention in mice. Single-cell RNA sequencing (scRNA-seq), <i>IP6K3</i> overexpression and knockdown, liquid chromatography–tandem mass spectrometry, and co-immunoprecipitation were used to explore the underlying mechanism by which IP6K3 regulates MASLD.</p> Results <p>Hepatic IP6K3 was significantly upregulated in both patients with MASLD as well as mice, and exercise markedly attenuated hepatic IP6K3 expression in MASLD mice. Hepatocyte-specific <i>Ip6k3</i> deletion conferred resistance to MASLD-induced liver injury. scRNA-seq revealed that these protective effects were related to enhanced BCAA degradation and inhibition of ferroptosis. Further studies showed that BCAA degradation was dependent on branched-chain aminotransferase 2 (BCAT2). In vitro, <i>IP6K3</i> overexpression exacerbated BCAA-promoted ferroptosis, which was rescued by ferrostatin-1. Conversely, <i>IP6K3</i> knockdown prevented ferroptosis, and this effect was abolished by inhibiting BCAT2. Mechanistically, elevated IP6K3 in MASLD could bind to heterogeneous nuclear ribonucleoprotein K (HNRNPK) in hepatocytes. Exercise-downregulated IP6K3 facilitated HNRNPK release, thereby stabilizing <i>BCAT2</i> mRNA, promoting BCAA catabolism, and ultimately preventing ferroptosis in MASLD.</p> Conclusions <p>Our study identifies IP6K3 as a key molecule in exercise-induced protection against MASLD, and suggests that IP6K3 inhibition might represent a potential pharmacological strategy for MASLD intervention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exercise suppresses IP6K3 to modulate BCAA metabolism and ferroptosis in MASLD

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月8日

查看全文
  • Zi-Chen Li,
  • Fang-Fang Xu,
  • Yi Zhao,
  • Chen-Rui Shen,
  • Xin-Yi Song,
  • Yu-Ping Xu,
  • Hui Guo,
  • Jiang-Tao Fu,
  • Xuan-Yi Tao,
  • Jun Ren,
  • Ling Lin,
  • Dong-Jie Li,
  • Hui Fu,
  • Fu-Ming Shen

摘要

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to branched-chain amino acid (BCAA) dysmetabolism and ferroptosis, and exercise is considered protective, yet the underlying mechanisms remain unclear.

Methods

Integrated bioinformatic analyses of public datasets were performed to identify key regulators of MASLD. Hepatic inositol hexakisphosphate kinase 3 (IP6K3) expression was examined in liver samples from patients with MASLD as well as mice. The functional role of IP6K3 was assessed by either hepatocyte-specific Ip6k3 deletion or exercise intervention in mice. Single-cell RNA sequencing (scRNA-seq), IP6K3 overexpression and knockdown, liquid chromatography–tandem mass spectrometry, and co-immunoprecipitation were used to explore the underlying mechanism by which IP6K3 regulates MASLD.

Results

Hepatic IP6K3 was significantly upregulated in both patients with MASLD as well as mice, and exercise markedly attenuated hepatic IP6K3 expression in MASLD mice. Hepatocyte-specific Ip6k3 deletion conferred resistance to MASLD-induced liver injury. scRNA-seq revealed that these protective effects were related to enhanced BCAA degradation and inhibition of ferroptosis. Further studies showed that BCAA degradation was dependent on branched-chain aminotransferase 2 (BCAT2). In vitro, IP6K3 overexpression exacerbated BCAA-promoted ferroptosis, which was rescued by ferrostatin-1. Conversely, IP6K3 knockdown prevented ferroptosis, and this effect was abolished by inhibiting BCAT2. Mechanistically, elevated IP6K3 in MASLD could bind to heterogeneous nuclear ribonucleoprotein K (HNRNPK) in hepatocytes. Exercise-downregulated IP6K3 facilitated HNRNPK release, thereby stabilizing BCAT2 mRNA, promoting BCAA catabolism, and ultimately preventing ferroptosis in MASLD.

Conclusions

Our study identifies IP6K3 as a key molecule in exercise-induced protection against MASLD, and suggests that IP6K3 inhibition might represent a potential pharmacological strategy for MASLD intervention.